Prakash S, Chang T M
Department of Physiology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Artif Cells Blood Substit Immobil Biotechnol. 1996 May;24(3):201-18. doi: 10.3109/10731199609117436.
We report a novel approach for plasma urea and ammonia removal using artificial cells microencapsulated genetically engineered bacteria E. coli DH5 cells. This has been evaluated for use in a column bioreactor for removing plasma urea and ammonia. It has also been evaluated in uremic rats for urea removal by oral administration. In 30 minutes, microencapsulated E. coli DH5 in a column bioreactor in-vitro lowered plasma urea to 10.47 +/- 3.45 mg/dl from 45.85 +/- 2.98 mg/dl and lowered plasma ammonia concentration to 46.00 +/- 4.00 microM from 679 +/- 32 microM/1. The efficiency of this bioreactor for plasma urea and ammonia removal is much higher than any other available methods. Initial plasma urea and ammonia concentration does not affect the plasma urea and ammonia removal efficiency of the column bioreactor. In in-vivo studies of oral administration to uremic rats, both free and encapsulated bacteria both lowered systemic urea from the initial 52.08 (S.D.2.37) mg/dl to 10.58 (S.D.0.85) mg/dl. Unlike free bacteria, microencapsulated bacteria was not retained in the intestine.
我们报告了一种使用微囊化基因工程大肠杆菌DH5细胞去除血浆尿素和氨的新方法。已对其在柱式生物反应器中用于去除血浆尿素和氨的效果进行了评估。还通过口服给药在尿毒症大鼠中对其尿素去除效果进行了评估。在30分钟内，柱式生物反应器中的体外微囊化大肠杆菌DH5将血浆尿素浓度从45.85±2.98mg/dl降至10.47±3.45mg/dl，并将血浆氨浓度从679±32μM/1降至46.00±4.00μM。这种生物反应器去除血浆尿素和氨的效率远高于任何其他现有方法。初始血浆尿素和氨浓度不影响柱式生物反应器去除血浆尿素和氨的效率。在对尿毒症大鼠口服给药的体内研究中，游离细菌和微囊化细菌均将全身尿素浓度从初始的52.08（标准差2.37）mg/dl降至10.58（标准差0.85）mg/dl。与游离细菌不同，微囊化细菌不会滞留在肠道中。
